Research Article

Stability of a Two-Strain Tuberculosis Model with General Contact Rate

Hai-Feng Huo,¹ Shuai-Jun Dang,¹ and Yu-Ning Li²

¹ Institute of Applied Mathematics, Lanzhou University of Technology, Lanzhou, Gansu 730050, China
² Department of Pediatrics, First Hospital of Lanzhou University, Lanzhou, Gansu 730000, China

Correspondence should be addressed to Hai-Feng Huo, hfhuo@lut.cn

Received 1 November 2010; Accepted 31 December 2010

Academic Editor: D. Anderson

Copyright © 2010 Hai-Feng Huo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

A two-strain tuberculosis model with general contact rate which allows tuberculosis patients with the drug-sensitive *Mycobacterium tuberculosis* strain to be treated is presented. The model includes both drug-sensitive and drug-resistant strains. A detailed qualitative analysis about positivity, boundedness, existence, uniqueness and global stability of the equilibria of this model is carried out. Analytical results of the model show that the quantities $R_1$ and $R_2$, which represent the basic reproduction numbers of the sensitive and resistant strains, respectively, provide the threshold conditions which determine the competitive outcomes of the two strains. Numerical simulations are also conducted to confirm and extend the analytic results.

1. Introduction

Tuberculosis (TB), an infectious disease caused by *Mycobacterium tuberculosis* (*M. tuberculosis*), is one of the world’s leading causes of infectious mortality. According to the World Health Organization (WHO), one third of the world’s population is infected with *M. tuberculosis*, leading to between two and three millions death each year. At present, about 95% of the estimated 8 million new cases of TB occurring each year are in developing countries, where 80% occur among people between the ages of 15 and 59 years [1]. For the time being, TB is becoming a world-wide problem. War, famine, homelessness, and a lack of medical care all contribute to the increasing incidence of tuberculosis among disadvantaged persons. Since TB is easily transmissible between persons, the increase in TB in any segment of the population represents a threat to all segments of the population. Sub-Saharan Africa remains the epicenter of the epidemic, but India, China, Indonesia, Bangladesh and Pakistan together account for more than half of the cases in the world [2]. TB was assumed to be on its way out in developed countries until the number of TB cases began to increase in the 1980s. With this return, we face the paradox of a well-known bacteria, fully treatable with
efficient and affordable drugs according to internationally recommended guidelines, which yet causes increasing human suffering and death. Active TB cases may be pulmonary or extrapulmonary, but pulmonary cases are more infectious and form the bulk of most cases of active TB. The usual symptoms of active TB include fatigue, high fever, night sweats, loss of appetite, and a cough, but confirmation of active TB requires a positive sputum culture. Extrapulmonary accounts for between 5% and 30% of the total cases and may affect any part of the body. *M. tuberculosis* droplets are released into the air by sneezing and coughing of infectious individuals. *Tubercle bacillus* carried by such droplets live in the air for a short period of time [3]; it is believed that occasional contacts with an infectious individual rarely lead to transmission. TB is described as a slow disease because of its long and variable latency period distribution and its short and relatively narrow infectious period distribution. Individuals who are latently infected are neither clinically ill nor capable of transmitting TB [4]. Most latently infected individuals do not become infectious (active TB). About 5%–10% of the latently infected individuals develop active TB, that is, about 90%–95% remain latently infected.

Antituberculosis drugs are a two-edged sword. While they destroy pathogenic *M. tuberculosis*, they also select for drug-resistant bacteria against with those drugs which are then ineffective. Global surveillance has shown that drug-resistant TB is widespread and is now a threat to TB control programs in many countries. The WHO distinguishes between two types of resistance: acquired resistance—resistance among previously treated patients; and primary resistance—resistance among new cases. In all regions studied, prevalence of acquired resistance is higher than prevalence of primary resistance, but the size of this difference varies between regions [5]. Treatment of TB consists of a combination of different drugs to avoid acquisition of resistance. Despite these precautions, drug resistance continues to emerge being favoured by the long duration of treatment and improper use of the antibiotics. Drug resistant TB has higher rates of treatment failure and longer periods of infectiousness in part due to the time lapse between TB diagnosis and obtaining drug-sensitivity test results [6]. In general, tuberculosis can be treated with antibiotics. However, most worrisome is resistance to the two first-line drugs, isoniazid and rifampicin, defined as multidrug resistance(MDR)-TB, which is an emerging problem of great importance to public health, with higher mortality rates than drug-sensitive TB, particularly in immunocompromised patients. MDR-TB patients require treatment with more toxic second line drugs and remain infectious for longer than patients infected with drug-sensitive strains, incurring higher costs due to prolonged hospitalization.

Mathematical models can provide useful tools to analyze the spread and control of infectious diseases [7]. Different mathematical models for TB have been formulated and studied [3, 5, 8–16]. In most of the epidemics models for TB discussed in the literature, the question of contact rate has not been a central one. Nevertheless, the mode of transmission is crucially important for two reasons. First, it determines the probable response of the disease to control, second, the objective in many models of disease in animals is to predict what will happen when a pathogen is introduced into a system in which it does not currently exist [17]. Even more important, several laboratory studies have found that the mass action incidence rate is inadequate for describing pathogen transmission and standard incidence rate is considered, for human disease, more accurate than mass action incidence rate [17]. Moreover, epidemic models with nonlinear incidence rate have recently attracted a great deal of attention from mathematical models [18–22]. In fact, the incidence of a disease which is the number of new cases per unit time plays an important role in the study of mathematical epidemiology. Thieme and Castillo-Chavez [23] argued that the general form...
Abstract and Applied Analysis

of a population-size-dependent incidence should be written as $\beta C(N)SI/N$, where $S$ and $I$ are the numbers of susceptible and infective at time $t$, respectively, $\beta$ is the probability of transmitting the infection between two individuals taking part in a contact per unit time, $C(N)$ is the probability for an individual to take part in a contact and $N$ is the size of the total population. In [24], Zhang and Ma think the above incidence frequently takes two forms in most of the literature. When $C(N) = N$, the corresponding incidence is the bilinear form $\beta NSI/N = \beta SI$. When $C(N) = \lambda$, the corresponding incidence $\lambda SI/N$ is called standard form. When the total population size $N$ is not quite large, since the number of contacts made by an individual per unit time should increase as the total population size $N$ increases, the bilinear form would be suitable, but when the total population size is too large, since the number of contacts made by an infective per unit time should be limited, or should grow less rapidly as the total population size $N$ increases, the bilinear form is not suitable and the standard form may be more realistic [24]. Therefore, the two forms of incidence mentioned above are actually two extreme cases for the total population size $N$ being very small and very large, respectively. Moreover, Heesterbeek and Metz [25] derived the expression for the saturating contact rate of individuals contacts in a population that mixes randomly, that is,

$$C(N) = \frac{bN}{1 + bN + \sqrt{1 + 2bN}},$$

(1.1)

where $C(N)$ is nondecreasing and $C(N)/N$ is nonincreasing.

In Bowong and Tewa [26], a SEI type of tuberculosis model with a general contact rate is proposed to study the global asymptotically stability of disease-free equilibrium and endemic equilibrium. The stability of equilibria is derived through the use of Lyapunov stability theory and LaSalle’s invariant set theorem. Nevertheless, the effect of drug-resistant strain of tuberculosis is not taken into account in their article. In this paper, we study a tuberculosis model with general contact rate that includes explicitly both drug-sensitive strain and drug-resistant strain. We adapt the approach of Bowong and Tewa [26] for modeling the effective chemoprophylaxis (given to latently infected individuals) and therapeutic treatments (given to infectious). We extend their model by including the latently infected with resistant strain class and infectious with resistant strain class. The new model allows us to examine the effects of drug treatment on the prevalence of both drug-sensitive and drug-resistant strains. Mathematical properties of the model system are studied both analytically and numerically. It is shown that the system has three possible equilibrium points including an endemic equilibrium at which both strains are present. A detailed analysis of global asymptotically stability is conducted, which shows that the dynamic behaviors of the system are determined by two quantities, $R_1$ and $R_2$, which represent the basic reproduction numbers of the sensitive and resistant strains. Without regard to disease-induced death rate, we prove that the disease-free equilibrium is globally asymptotically stable when $R_1 < 1$, $R_2 < 1$, the unique drug-resistant-TB-strain-only equilibrium exists and is globally asymptotically stable when $R_1 < 1 < R_2$. As for the unique interior equilibrium, existence, uniqueness and global stability can be proved under certain conditions.

The paper is organized as follows. In Section 2, we formulate a two-strain tuberculosis model with general contact rate. The threshold conditions for the existence and uniqueness equilibria are derived and the global asymptotically stability of equilibria are proved in Sections 3 and 4 is devoted to numerical simulations. In Section 5, we summarize the findings and conclusions.
2. Model Description

According to the transmitted features of TB, we subdivide the population into susceptible individuals \( S \), those exposed to drug-sensitive TB \( E_1 \), individuals with symptoms of TB and drug-sensitive \( I_1 \), those exposed to drug-resistant TB \( E_2 \) and those displaying symptoms of TB and drug-resistant \( I_2 \), the total number of population at time \( t \) is given by

\[
N(t) = S(t) + E_1(t) + I_1(t) + E_2(t) + I_2(t).
\]

The model is represented by the transfer diagram in Figure 1. Here, \( \Lambda \) is the recruitment rate, \( \mu \) is nondisease related death rate. Since exposed individuals are not capable of transmitting the disease, we assume that susceptible may become infected only through contacts with active infectious individual at a rate \( \beta_i(N)I_i \), \( i = 1, 2 \), where \( i = 1 \) and \( i = 2 \) represent rates of infection by drug-sensitive strain and drug-resistant strain, and the transmission coefficient \( \beta_i(N) \) is a nonnegative \( C^2 \) function of the total population \( N \). Susceptible are infected with drug-sensitive strain and drug-resistant strain entering classes \( E_1 \) and \( E_2 \), respectively. For simplicity, we only account for treatment of sensitive strain, we assume that chemoprophylaxis of individuals in \( E_1 \) reduces their reactivation at a constant rate \( r_1 \) and that the initiation of therapeutics immediately removes individuals in \( I_1 \) from active status and places them into exposed class at a constant rate \( r_2 \). The time before individuals in \( E_1 \) who does not received effective chemoprophylaxis become infectious is assumed to satisfy an exponential distribution, with mean waiting time \( 1/k_1 \). Thus, individuals leave the class \( E_1 \) to the class \( I_1 \) at a constant rate \( k_1(1 - r_1) \). The time before individuals in \( E_2 \) become infectious is also assumed to satisfy an exponential distribution, with mean waiting time \( 1/k_2 \). Thus, individuals leave the class \( E_2 \) to the class \( I_2 \) at a constant rate \( k_2 \). Individuals sick with drug-sensitive strain receive treatment at rate \( r_2 \) and a proportion \( pr_2 \) respond to treatment and move into exposed class \( E_1 \), in the remaining proportion \( (1 - p)r_2 \), inappropriate treatment results in the development of drug-resistant strain and the individuals move into class \( E_2 \). Individuals in the infectious class \( I_1 \) and \( I_2 \) suffer additional disease-induced death at rate \( d_1 \) and \( d_2 \), where \( d_2 > d_1 \). Then the following two strains tuberculosis model is formulated

\[
\begin{align*}
S' &= \Lambda - \beta_1(N)SI_1 - \beta_2(N)SI_2 - \mu S, \\
E_1' &= \beta_1(N)SI_1 + pr_2I_1 - k_1(1 - r_1)E_1 - \mu E_1, \\
I_1' &= k_1(1 - r_1)E_1 - (r_2 + \mu + d_1)I_1, \\
E_2' &= \beta_2(N)SI_2 + (1 - p)r_2I_1 - (\mu + k_2)E_2, \\
I_2' &= k_2E_2 - (\mu + d_2)I_2,
\end{align*}
\]

where \( \Lambda, k_1, k_2, r_1, \) and \( r_2 \) are assumed to be positive and \( p \in [0, 1] \). It is natural to assume that the transmission coefficient \( \beta_1(N), \beta_2(N) \) satisfies the following conditions:

\[
\beta_1(N) > 0, \quad \beta_1'(N) \leq 0, \quad (N\beta_1(N))' \geq 0, \\
\beta_2(N) > 0, \quad \beta_2'(N) \leq 0, \quad (N\beta_2(N))' \geq 0.
\]
Theorem 2.1. If the initial data remains positive for all time and that \( \beta \) there exists a \( \Gamma \) invariant and all solutions starting in \( I \) approach, enter, or stay in \( \Gamma \), where

\[
C(N) = \frac{bN}{1 + bN + \sqrt{1 + 2bN}}. \tag{2.4}
\]

### 2.1. Positivity and Boundedness

System (2.2) describes human population and therefore it is necessary to prove that all the variables \( S, E_1, I_1, E_2, I_2 \) are nonnegative for all time. Solutions of system (2.2) with positive initial data remains positive for all time \( t \geq 0 \) and are bounded.

**Theorem 2.1.** If \( S(0) \geq 0, E_1(0) \geq 0, I_1(0) \geq 0, E_2(0) \geq 0, I_2(0) \geq 0 \), the solutions \( S(t), E_1(t), I_1(t), E_2(t), I_2(t) \) of system (2.2) are positive for \( t \geq 0 \). For system (2.2), the region \( \Gamma \) is positively invariant and all solutions starting in \( \Gamma \) approach, enter, or stay in \( \Gamma \), where

\[
\Gamma = \left\{ (S(t), E_1(t), I_1(t), E_2(t), I_2(t)) \in \mathbb{R}_+^5 : N(t) \leq \frac{\Lambda}{\mu} \right\}. \tag{2.5}
\]

**Proof.** Under the given initial conditions, it is easy to prove that the solutions of the system (2.2) are positive; if not, we assume a contradiction: that there exists a first time \( t_1 \) such that

\[
S(t_1) = 0, \quad S'(t_1) < 0, \quad E_1(t) \geq 0, \quad I_1(t) \geq 0, \quad E_2(t) \geq 0, \quad I_2(t) \geq 0, \quad \text{for} \ 0 < t < t_1, \tag{2.6}
\]

there exists a \( t_2 \)

\[
E_1(t_2) = 0, \quad E_1'(t_2) < 0, \quad S(t) \geq 0, \quad I_1(t) \geq 0, \quad E_2(t) \geq 0, \quad I_2(t) \geq 0, \quad \text{for} \ 0 < t < t_2, \tag{2.7}
\]

there exists a \( t_3 \)

\[
I_1(t_3) = 0, \quad I_1'(t_3) < 0, \quad S(t) \geq 0, \quad E_1(t) \geq 0, \quad E_2(t) \geq 0, \quad I_2(t) \geq 0, \quad \text{for} \ 0 < t < t_3, \tag{2.8}
\]
there exists a $t_4$

$$E_2(t_4) = 0, \quad E_2'(t_4) < 0, \quad S(t) \geq 0, \quad E_1(t) \geq 0, \quad I_1(t) \geq 0, \quad I_2(t) \geq 0, \quad \text{for } 0 < t < t_4,$$

(2.9)
or there exists a $t_5$

$$I_2(t_5) = 0, \quad I_2'(t_5) < 0, \quad S(t) \geq 0, \quad E_1(t) \geq 0, \quad I_1(t) \geq 0, \quad E_2(t) \geq 0, \quad \text{for } 0 < t < t_5.$$

(2.10)

In the first case, we have

$$S'(t_1) = \Lambda > 0,$$

(2.11)

which is a contradiction meaning that $S(t) \geq 0, t \geq 0$. In the second case, we have

$$E_1'(t_2) = I_1(t_2)[\beta_1(N)S(t_2) + pr_2] \geq 0,$$

(2.12)

which is a contradiction meaning that $E_1(t) \geq 0, t \geq 0$. In the third case, we have

$$I_1'(t_3) = k_1(1-r_1)E_1(t_3) \geq 0,$$

(2.13)

which is a contradiction meaning that $I_1(t) \geq 0, t \geq 0$. In the fourth case, we have

$$E_2'(t_4) = \beta_2(N)S(t_4)I_2(t_4) + (1-p)r_2I_1(t_4) \geq 0,$$

(2.14)

which is a contradiction meaning that $E_2(t) \geq 0, t \geq 0$. In the fifth case, we have

$$I_2'(t_5) = k_2E_2(t_5) \geq 0,$$

(2.15)

which is a contradiction meaning that $I_2(t) \geq 0, t \geq 0$.

Thus, in all cases, $S(t), E_1(t), I_1(t), E_2(t), I_2(t)$ remain positive for $t \geq 0$. Let $(S(t), E_1(t), I_1(t), E_2(t), I_2(t)) \in \mathbb{R}_+^5$ be any solution with nonnegative initial condition, adding all equations in system (2.2) gives

$$N'(t) = \Lambda - \mu N - d_1I_1 - d_2I_2,$$

$$\leq \Lambda - \mu N.$$

(2.16)

It follows that

$$0 \leq N(t) \leq \frac{\Lambda}{\mu} + N(0)e^{-\mu t},$$

(2.17)
where $N(0)$ represents initial values of the total population. Thus $0 \leq N(t) \leq \Lambda/\mu$, as $t \to \infty$. Therefore all feasible solutions of system (2.2) enter the region

$$
\Gamma = \left\{ (S(t), E_1(t), I_1(t), E_2(t), I_2(t)) \in \mathbb{R}_+^5 : N(t) \leq \frac{\Lambda}{\mu} \right\}.
$$

Hence, $\Gamma$ is positively invariant and it is sufficient to consider solutions of system (2.2) in $\Gamma$. Existence, uniqueness and continuation results for system (2.2) hold in this region. It can be shown that $N(t)$ is bounded and all the solutions starting in $\Gamma$ approach, enter or stay in $\Gamma$.

3. Model Analysis

There are one disease-free equilibrium $P_0$ and two possible endemic equilibria for system (2.2), the endemic equilibria include boundary equilibrium $P_1$ (when only the drug-resistant TB-strain is present) and the interior equilibrium $P_2$ (when both strains exist).

3.1. Global Stability of the Disease-Free Equilibrium

The disease-free-equilibrium is given as

$$
P_0 = (S_0, 0, 0, 0), \quad S_0 = \frac{\Lambda}{\mu}.
$$

The basic reproduction number is defined as the number of secondary infections produced by a single infectious individual during the entire infectious period. In our case the reproduction number defines the number of secondary TB infections produced by a single active TB individual during the entire infectious period. Mathematically it is defined as the spectral radius of the next generation matrix [27]. To determine the stability of the disease-free steady state $P_0$, we use the results in van den Driessche and Watmough [27]. Reorder the components of $P_0$ as $E_1 = 0, I_1 = 0, E_2 = 0, I_2 = 0, S = \Lambda/\mu$. Set

$$
\mathcal{F} = \begin{bmatrix}
F_1 \\
F_2 \\
F_3 \\
F_4 \\
F_5
\end{bmatrix} = \begin{bmatrix}
\beta_1(N)S_1 \\
0 \\
\beta_2(N)S_2 \\
0 \\
0
\end{bmatrix},
$$

and

$$
\mathcal{U} = \begin{bmatrix}
k_1(1 - r_1)E_1 + \mu E_1 - pr_2I_1 \\
r_2I_1 + (\mu + d_1)I_1 - k_1(1 - r_1)E_1 \\
(\mu + k_2)E_2 - (1 - p)r_2I_1 \\
(\mu + d_2)I_2 - k_2E_2 \\
\mu S + \beta_1(N)S_1 + \beta_2(N)S_2 - \Lambda
\end{bmatrix}.
$$
The infected compartments are $E_1, I_1, E_2,$ and $I_2$. Thus

$$F = \begin{bmatrix}
0 & \beta_1(S_0)S_0 & 0 & 0 \\
0 & 0 & 0 & 0 \\
0 & 0 & 0 & \beta_1(S_0)S_0 \\
0 & 0 & 0 & 0 \\
\end{bmatrix},$$

$$V = \begin{bmatrix}
\mu + k_1(1 - r_1) & -pr_2 & 0 & 0 \\
-k_1(1 - r_1) & \mu + d_1 + r_2 & 0 & 0 \\
0 & -(1 - p)r_2 & \mu + k_2 & 0 \\
0 & 0 & -k_2 & \mu + d_2 \\
\end{bmatrix}. \quad (3.3)$$

The dominant eigenvalues of $FV^{-1}$ are given by

$$R_1 = \frac{k_1(1 - r_1)\beta_1(S_0)S_0}{(\mu + d_1 + r_2)(\mu + k_1(1 - r_1)) - k_1pr_2(1 - r_1)},$$

$$R_2 = \frac{k_2\beta_2(S_0)S_0}{(\mu + k_2)(\mu + d_2)}, \quad (3.4)$$

where $R_1$ and $R_2$ are reproduction numbers for drug-sensitive TB strain only and drug-resistant TB strain only, respectively. It implies that the spectral radius of the matrix $FV^{-1}$ is

$$\rho(FV^{-1}) = \max\{R_1, R_2\}. \quad (3.5)$$

If $R_1 < 1$, and $R_2 < 1$, then $\rho(FV^{-1}) < 1$. By Theorem 3.2 in van den Driessche and Watmough [27], we know that the disease-free steady state $P_0$ is locally asymptotically stable, $P_0$ is unstable if $R_1 > 1$ or $R_2 > 1$. The following theorems provide the global stability of the disease-free equilibrium.

To conduct an analytical analysis of global asymptotical behaviors of the disease-free equilibrium point, first of all, we assume that there is no disease-induced death rate, that is, $d_1 = 0, d_2 = 0$. Consequently, the total population size $N(t)$ satisfies the equation $dN/dt = \Lambda - \mu N$ and $N(t) \to \Lambda/\mu$ as $t \to \infty$. Using results from Castillo-Chavez and Thieme [28] and Mischaikow et al. [29], we can obtain analytical results by considering the following limiting system of (2.2) in which the total population is assumed to be constant $N = S_0 = \Lambda/\mu$:

$$E_1' = \beta_1(S_0)I_1(S_0 - E_1 - I_1 - E_2 - I_2) + pr_2I_1 - (\mu + k_1(1 - r_1))E_1,$$

$$I_1' = k_1(1 - r_1)E_1 - (r_2 + \mu)I_1,$$

$$E_2' = \beta_2(S_0)I_2(S_0 - E_1 - I_1 - E_2 - I_2) + (1 - p)r_2I_1 - (\mu + k_2)E_2,$$

$$I_2' = k_2E_2 - \mu I_2. \quad (3.6)$$
Notice that the $S$ equation is eliminated from (3.6) and the variable $S$ is replaced by $S_0 - E_1 - I_1 - E_2 - I_2$. By introducing the fractions

$$x_1 = \frac{E_1}{N}, \quad x_2 = \frac{I_1}{N}, \quad y_1 = \frac{E_2}{N}, \quad y_2 = \frac{I_2}{N},$$

we obtain the equivalent limiting system from (3.6)

$$x'_1 = S_0\beta_1(S_0)(1 - x_1 - x_2 - y_1 - y_2)x_2 + pr_2x_2 - (\mu + k_1(1 - r_1))x_1,$$

$$x'_2 = k_1(1 - r_1)x_1 - (\mu + r_2)x_2,$$

$$y'_1 = S_0\beta_2(S_0)(1 - x_1 - x_2 - y_1 - y_2)y_2 + (1 - p)r_2x_2 - (\mu + k_2)y_1,$$

$$y'_2 = k_2y_1 - \mu y_2.$$ (3.8)

Obviously

$$0 \leq x_1 + x_2 + y_1 + y_2 \leq 1,$$ (3.9)

for all time $t \geq 0$.

For a bounded real-valued function $f$ on $[0, \infty)$, we define

$$f^\infty = \lim_{t \to \infty} \inf \{f(t)\}, \quad f_\infty = \lim_{t \to \infty} \sup \{f(t)\}.$$ (3.10)

**Lemma 3.1** (see [30]). Let $f : [0, \infty) \to \infty$ be bounded and continuously differentiable. Then there are sequences $t_n, s_n \to \infty$ with the following properties:

$$f(t_n) \to f_\infty, \quad f'(t_n) \to 0,$$

$$f(s_n) \to f^\infty, \quad f'(s_n) \to 0,$$ (3.11)

for $n \to \infty$.

**Theorem 3.2.** In the absence of disease-induced death rate, the disease-free equilibrium $P_0$ of system (2.2) is globally asymptotically stable if $R_1 < 1, R_2 < 1$.

**Proof.** By Lemma 3.1 and the $x'_2, y'_2$ equations in (3.8) we have

$$x^\infty_2 \leq \frac{k_1(1 - r_1)}{\mu + r_2}x^\infty_1, \quad y^\infty_2 \leq \frac{k_2}{\mu} y^\infty_1.$$ (3.12)

Using the $x'_1$ equation in (3.8) and choosing $t_n \to \infty$ such that

$$x_1(t_n) \to x^\infty_1, \quad x'_1(t_n) \to 0, \quad t \to \infty,$$ (3.13)
we get

\[0 \leq S_0 \beta_1(S_0)(1 - x_1 - x_2 - y_1 - y_2) x_2^\infty - (\mu + k_1(1 - r_1)) x_1^\infty\]

\[\leq S_0 \beta_1(S_0) x_2^\infty - (\mu + k_1(1 - r_1)) x_1^\infty\]

\[\leq S_0 \beta_1(S_0) \frac{k_1(1 - r_1)}{\mu + r_2} x_1^\infty - (\mu + k_1(1 - r_1)) x_1^\infty\]

\[\leq (\mu + k_1(1 - r_1)) x_1^\infty \left[ \frac{k_1(1 - r_1) S_0 \beta_1(S_0)}{\mu + k_1(1 - r_1)} - 1 \right] \]  

\[\leq (\mu + k_1(1 - r_1)) x_1^\infty \left[ \frac{k_1(1 - r_1) S_0 \beta_1(S_0)}{(\mu + r_2)(\mu + k_1(1 - r_1)) - k_1 pr_2(1 - r_1)} - 1 \right] \]

\[= (\mu + k_1(1 - r_1)) x_1^\infty (R_1 - 1).\]  

It is shown that \(x_1^\infty \leq 0\) since \(R_1 < 1\), as \(x_2^\infty \geq 0\), we have that \(x_1^\infty = 0\). The inequalities in (3.12) also imply that \(x_2^\infty = 0\).

Using the \(y_1'\) equation in (3.8) and choosing \(s_n \to \infty\) such that

\[y_1(s_n) \to y_1^\infty, \quad y_1'(s_n) \to 0, \quad t \to \infty,\]

we get

\[0 \leq S_0 \beta_2(S_0)(1 - x_1 - x_2 - y_1 - y_2) y_2^\infty - (\mu + k_2) y_1^\infty\]

\[\leq S_0 \beta_2(S_0) y_2^\infty - (\mu + k_2) y_1^\infty\]

\[\leq S_0 \beta_2(S_0) \frac{k_2}{\mu} y_1^\infty - (\mu + k_2) y_1^\infty\]

\[\leq (\mu + k_2) y_1^\infty \left[ \frac{k_2 S_0 \beta_2(S_0)}{\mu (\mu + k_2)} - 1 \right] \]

\[= (\mu + k_2) y_1^\infty (R_2 - 1).\]

It is shown that \(y_1^\infty \leq 0\) since \(R_2 < 1\), as \(y_1^\infty \geq 0\), we have that \(y_1^\infty = 0\). The inequalities in (3.12) also imply that \(y_2^\infty = 0\).

Hence

\[\lim_{t \to \infty} x_1(t) = \lim_{t \to \infty} x_2(t) = \lim_{t \to \infty} y_1(t) = \lim_{t \to \infty} y_2(t) = 0.\]

Therefore, the disease-free equilibrium \(P_0\) is globally asymptotically stable. \(\square\)

Next, we consider that there is disease-induced death rate, which means that \(d_1 > 0\), \(d_2 > 0\). Then, we can get the following theorem.
Theorem 3.3. For $d_1 > 0$, $d_2 > 0$, the disease-free equilibrium $P_0$ of system (2.2) is globally asymptotically stable if $R_1 < 1 - k_2 r_2 (1 - p) / ((\mu + d_1 + r_2)(\mu + k_1(1 - r_1)) - k_1 p r_2 (1 - r_1))$, $R_2 < 1$.

Proof. Let us consider the following Lyapunov function:

$$V(E_1, I_1, E_2, I_2) = k_1(1 - r_1)E_1 + (\mu + k_1(1 - r_1))I_1 + k_2 E_2 + (\mu + k_2)I_2.$$  \hspace{1cm} (3.18)

Its time derivative along the solutions of system (2.2) satisfies

$$V = k_1(1 - r_1)E_1 + (\mu + k_1(1 - r_1))I_1 + k_2 E_2 + (\mu + k_2)I_2$$

$$= k_1(1 - r_1)[\beta_1(N)S I_1 + pr_2 I_1 - (\mu + k_1(1 - r_1))E_1]$$

$$+ (\mu + k_1(1 - r_1))[k_1(1 - r_1)E_1 - (\mu + d_1 + r_2)I_1]$$

$$+ k_2[\beta_2(N)S I_2 + (1 - p)r_2 I_1 - (\mu + k_2)E_2]$$

$$+ (\mu + k_2)[k_2 E_2 - (\mu + d_2)I_2],$$

$$= [k_1(1 - r_1)\beta_1(N)S + k_1(1 - r_1)pr_2 - (\mu + d_1 + r_2)(\mu + k_1(1 - r_1))]I_1$$

$$+ [k_2\beta_2(N)S - (\mu + d_2)(\mu + k_2)]I_2$$

$$+ k_2 r_2 (1 - p)I_1.$$  \hspace{1cm} (3.19)

Now, using (2.3), one has $\beta_1(N)S \leq \beta_1(S_0)S_0$, $\beta_2(N)S \leq \beta_2(S_0)S_0$, then

$$V \leq [(\mu + d_1 + r_2)(\mu + k_1(1 - r_1)) - k_1(1 - r_1)pr_2] (R_1 - 1) I_1 + k_2 r_2 (1 - p)I_1$$

$$+ (\mu + d_2)(\mu + k_2)(R_2 - 1)I_2,$$

$$= [(\mu + d_1 + r_2)(\mu + k_1(1 - r_1)) - k_1(1 - r_1)pr_2] (R_1 - 1) + k_2 r_2 (1 - p)I_1$$

$$+ (\mu + d_2)(\mu + k_2)(R_2 - 1)I_2.$$  \hspace{1cm} (3.20)

Since

$$[(\mu + d_1 + r_2)(\mu + k_1(1 - r_1)) - k_1 p r_2 (1 - r_1)]$$

$$= \mu (\mu + d_1 + r_2) + k_1 (1 - r_1)(\mu + d_1) + k_1 r_2 (1 - r_1) - k_1 p r_2 (1 - r_1)$$

$$= \mu (\mu + d_1 + r_2) + k_1 (1 - r_1)(\mu + d_1) + k_1 r_2 (1 - r_1)(1 - p)$$

$$\geq 0,$$

and $R_1 < 1 - k_2 r_2 (1 - p) / ((\mu + d_1 + r_2)(\mu + k_1(1 - r_1)) - k_1 p r_2 (1 - r_1)) \leq 1$, we have

$$[(\mu + d_1 + r_2)(\mu + k_1(1 - r_1)) - k_1(1 - r_1)pr_2] (R_1 - 1) + k_2 r_2 (1 - p) \leq 0.$$  \hspace{1cm} (3.21)

Thus, $V \leq 0$ if $R_1 < 1 - k_2 r_2 (1 - p) / ((\mu + d_1 + r_2)(\mu + k_1(1 - r_1)) - k_1 p r_2 (1 - r_1))$, $R_2 < 1$. It is obvious that $V = 0$ if and only if $I_1 = 0$, $I_2 = 0$. Then, the largest invariant set of system...
(2.2) on the set \( \{(S, E_1, I_1, E_2, I_2) \in \mathbb{R}_+^5, \mathcal{V}(E_1, I_1, E_2, I_2) = 0\} \) is the disease-free equilibrium \( P_0 \). Therefore, it follows from LaSalle’s invariance principle [31, 32] that \( P_0 \) is globally stable if \( R_1 < 1 - k_2 r_2 (1 - p) / ((\mu + d_1 + r_2) (\mu + k_1 (1 - r_1)) - k_1 p r_2 (1 - r_1)) \). \( R_2 < 1 \).

\[ \text{3.2. Existence and Uniqueness of the Drug-Resistant-TB-Strain-Only Equilibrium} \]

Here, we present a result concerning the existence and uniqueness of the drug-resistant-TB-strain-only equilibrium for the system (2.2). To do this, we shall make use of the basic reproduction ratio \( R \).

Let \( P_1 = (\hat{S}, 0, 0, \hat{E}_2, \hat{I}_2) \) be boundary equilibrium of system (2.2). Then, the boundary equilibrium can be obtained by setting the right-hand side of each differential equations in system (2.2) equal to zero with the exception of second and third equation, giving

\[
\Lambda - \beta_2 \left( \hat{N} \right) \hat{S} \hat{I}_2 - \mu \hat{S} = 0,
\]

\[
\beta_2 \left( \hat{N} \right) \hat{S} \hat{I}_2 - (\mu + k_2) \hat{E}_2 = 0,
\]

\[
k_2 \hat{E}_2 - (\mu + d_2) \hat{I}_2 = 0,
\]

adding the above three equations, we have

\[
\Lambda - \mu \hat{N} - d_2 \hat{I}_2 = 0.
\]

Using (3.24), the first and second equation of (3.23), we can easily express \( \hat{S}, \hat{E}_2 \) and \( \hat{I}_2 \) in terms of \( \hat{N} \) in the form:

\[
\hat{S} = \frac{\Lambda d_2}{\mu d_2 + \beta_2 \left( \hat{N} \right) \left( \Lambda - \mu \hat{N} \right)},
\]

\[
\hat{E}_2 = \frac{\Lambda \beta_2 \left( \hat{N} \right) \left( \Lambda - \mu \hat{N} \right)}{(\mu + k_2) \left[ \mu d_2 + \beta_2 \left( \hat{N} \right) \left( \Lambda - \mu \hat{N} \right) \right]},
\]

\[
\hat{I}_2 = \frac{\Lambda - \mu \hat{N}}{d_2}.
\]

Substituting \( \hat{S}, \hat{E}_2, \hat{I}_2 \) in the third equations of (3.23) yields

\[
\left( \Lambda - \mu \hat{N} \right) F \left( \hat{N} \right) = 0,
\]

where

\[
F \left( \hat{N} \right) = \Lambda k_2 d_2 \beta_2 \left( \hat{N} \right) - (\mu + k_2) (\mu + d_2) \left[ \mu d_2 + \beta_2 \left( \hat{N} \right) \left( \Lambda - \mu \hat{N} \right) \right].
\]
Abstract and Applied Analysis

Clearly, \( \Lambda - \mu \hat{N} = 0 \) is a fixed point of (3.23), which corresponds to the disease-free equilibrium \( P_0 \). Since \( \hat{N} \in [0, S_0] \), we get

\[
F(0) = \Lambda k_2 d_2 \beta_2(0) - (\mu + k_2)(\mu + d_2)[\mu d_2 + \Lambda \beta_2(0)]
= \Lambda k_2 d_2 \beta_2(0) - [\mu^2 + \mu(d_2 + k_2)][\mu d_2 + \Lambda \beta_2(0)]
= \Lambda k_2 d_2 \beta_2(0) - [\mu^2 + \mu(d_2 + k_2)] - \Lambda d_2 k_2 \beta_2(0) - \mu k_2 d_2^2
= -[\mu^2 + \mu(k_2 + d_2)] \left[ \mu d_2 + \Lambda \beta_2(0) \right] - \mu k_2 d_2^2.
\]

\[
F(S_0) = \Lambda k_2 d_2 \beta_2(S_0) - \mu d_2 (\mu + k_2)(\mu + d_2)
= \mu \left[ k_2 d_2 \beta_2(S_0) S_0 - d_2 (\mu + k_2)(\mu + d_2) \right]
= \mu d_2 (\mu + k_2)(\mu + d_2) \left( \frac{k_2 \beta_2(S_0) S_0}{(\mu + k_2)(\mu + d_2)} - 1 \right)
= \mu d_2 (\mu + k_2)(\mu + d_2)(R_2 - 1).
\]

It appears that \( F(0) < 0 \) and \( F(S_0) > 0 \) when \( R_2 > 1 \). The existence of fixed point follows from the intermediate value-theorem. Now, \( F(\hat{N}) \) is monotone increasing, so that \( F(\hat{N}) = 0 \) has only one positive root in the interval \([0, S_0]\).

Thus, we have established the following result

**Lemma 3.4.** When \( R_2 > 1 \), the system (2.2) has a unique drug-resistant-TB-strain-only equilibrium \( P_1 = (\hat{S}, 0, 0, \hat{E}_2, \hat{I}_2) \) with \( \hat{S}, \hat{E}_2, \) and \( \hat{I}_2 \) all nonnegative.

### 3.3. Global Stability of the Drug-Resistant-TB-Strain-Only Equilibrium

**Theorem 3.5.** If \( R_1 < 1 < R_2 \), the drug-resistant-TB-strain-only equilibrium \( P_1 \) exists and is locally asymptotically stable.

**Proof.** Reorder the equilibrium \( P_1 \) as \((0, 0, \hat{E}_2, \hat{I}_2, \hat{S})\). Similarly as in the proof of locally stability of the disease-free steady state \( P_0 \), we have

\[
F_1 = \begin{bmatrix} 0 & \beta_1(\hat{N})\hat{S} \\ 0 & 0 \end{bmatrix},
V_1 = \begin{bmatrix} \mu + k_1(1 - r_1) & -pr_2 \\ -k_1(1 - r_1) & \mu + d_1 + r_2 \end{bmatrix},
F_1 V_1^{-1} = A \begin{bmatrix} k_1(1 - r_1)\beta_1(\hat{N})\hat{S} & (\mu + k_1(1 - r_1))\beta_1(\hat{N})\hat{S} \\ 0 & 0 \end{bmatrix},
\]

\( A \) is given by

\[
A = \begin{bmatrix} \lambda - \mu & -r_2 \\ -k_1(1 - r_1) \mu - d_1 & \lambda - \mu + d_1 + r_2 \end{bmatrix}.
\]
where

\[ A = \frac{1}{(\mu + d_1 + r_2)(\mu + k_1(1 - r_1)) - k_1pr_2(1 - r_1)}. \]  

(3.30)

The spectral radius of \( F_1V_1^{-1} \) is given by

\[
\rho\left(F_1V_1^{-1}\right) = \frac{k_1(1 - r_1)\beta_1\left(\bar{N}\right)\bar{S}}{(\mu + d_1 + r_2)(\mu + k_1(1 - r_1)) - k_1pr_2(1 - r_1)},
\]

(3.31)

\[
\leq \frac{k_1(1 - r_1)\beta_1\left(\bar{N}\right)\bar{N}}{(\mu + d_1 + r_2)(\mu + k_1(1 - r_1)) - k_1pr_2(1 - r_1)}.
\]

Since \((\beta_1(N)N)' \geq 0\), and \(\bar{N} \leq S_0\), then

\[
\beta_1\left(\bar{N}\right)\bar{N} \leq \beta_1(S_0)S_0,
\]

(3.32)

Thus

\[
\rho\left(F_1V_1^{-1}\right) \leq \frac{k_1(1 - r_1)\beta_1(S_0)S_0}{(\mu + d_1 + r_2)(\mu + k_1(1 - r_1)) - k_1pr_2(1 - r_1)} = R_1.
\]

(3.33)

As \(R_1 < 1\), we have \(\rho(F_1V_1^{-1}) < 1\), which implies that the drug-resistant-TB-strain-only equilibrium \(P_1\) is locally asymptotically stable by Theorem 3.2 in van den Driessche and Watmough [27].

The following theorem provides the global stability of drug-resistant-TB-strain-only equilibrium.

**Theorem 3.6.** If there is no disease-induced death rate, the drug-resistant-TB-strain-only equilibrium \(P_1\) is global asymptotically stable when \(R_1 < 1 < R_2\).

**Proof.** If \(R_1 < 1 < R_2\), from Theorem 3.5, \(P_1\) is locally asymptotically stable. In the following, we only need to prove that the \(P_1\) is a global attractor.

There is no disease-induced death rate, which means \(d_1 = d_2 = 0\), using a similar argument as in the proof of Theorem 3.2, we can show that if \(R_1 < 1\),

\[
\lim_{t \to \infty} x_1(t) = \lim_{t \to \infty} x_2(t) = 0.
\]

(3.34)

Then the equivalent limiting system of (3.6) is

\[
E'_2 = \beta_2(S_0)I_2(S_0 - E_2 - I_2) - (\mu + k_2)E_2,
\]

\[
I'_2 = k_2E_2 - \mu I_2.
\]

(3.35)
Let \((P, Q)\) be the vector field defined by system (3.35). Then for the Dulac function \(D(E_2, I_2) = 1/E_2 I_2\), there holds

\[
\frac{\partial}{E_2}(DP) + \frac{\partial}{I_2}(DQ) = -\frac{\beta_2(S_0)(S_0 - I_2)}{E_2^2} - \frac{k_2}{I_2^2} < 0. \tag{3.36}
\]

From Dulac’s criterion, we can see equivalent limiting system (3.35) does not have a limit cycle. Therefore, the local stability of \(P_1\) implies the global stability in \(\text{Int } \Gamma\). This completes the proof of Theorem 3.6.

**3.4. Existence and Uniqueness of the Interior Equilibrium**

First of all, we assume that

\[(W_1) \lim_{N \to 0}(1/\beta_1(N)) = +\infty,
(W_2) \beta_1(N)/\beta_2(N) = \beta_1/\beta_2,
\]
then, existence, uniqueness and global stability of interior equilibrium can be obtained. Let \(P_2 = (S^*, E_1^*, I_1^*, E_2^*, I_2^*)\) be interior equilibrium of system (2.2). Then, the interior equilibrium (steady state with \(I_1 > 0, I_2 > 0\)) can be obtained by setting the right-hand side of each of the five differential equations in system (2.2) equal to zero, giving

\[
\begin{align*}
\Lambda - \beta_1(N^*)S^* I_1^* - \beta_2(N^*)S^* I_2^* - \mu S^* &= 0, \\
\beta_1(N^*)S^* I_1^* + pr_2 I_1^* - k_1(1 - r_1) E_1^* - \mu E_1^* &= 0, \\
k_1(1 - r_1) E_1^* - (r_2 + \mu + d_1) I_1^* &= 0, \\
\beta_2(N^*)S^* I_2^* + (1 - p)r_1 I_1^* - (\mu + k_2) E_2^* &= 0, \\
k_2 E_2^* - (\mu + d_2) I_2^* &= 0,
\end{align*}
\]

adding the above five equations, we have

\[
\Lambda - \mu N^* - d_1 I_1^* - d_2 I_2^* = 0. \tag{3.38}
\]

Using (3.37) and (3.38), we get the following equivalent equations set

\[
\begin{align*}
\Lambda - \beta_1(N^*)S^* I_1^* - \beta_2(N^*)S^* I_2^* - \mu S^* &= 0, \\
\beta_1(N^*)S^* I_1^* + pr_2 I_1^* - k_3(1 - r_1) E_1^* - \mu E_1^* &= 0, \\
k_1(1 - r_1) E_1^* - (r_2 + \mu + d_1) I_1^* &= 0, \\
k_2 E_2^* - (\mu + d_2) I_2^* &= 0, \\
\Lambda - \mu N^* - d_1 I_1^* - d_2 I_2^* &= 0.
\end{align*}\tag{3.39}
\]
From (3.9), we have

\[ S^* = \frac{\beta(S_0)S_0}{R_1\beta_1(N^*)}, \]

\[ I_1^* = \frac{d_2(\Lambda - \mu S^*) - S^* \beta_2(N^*)(\Lambda - \mu N^*)}{d_2 S^* \beta_1(N^*) - d_1 S^* \beta_2(N^*)}, \]

\[ E_1^* = \frac{\mu + d_1 + r_2}{k_1(1 - r_2)} I_1^*, \]

\[ I_2^* = \frac{(\Lambda - \mu N^*)}{d_2} - \frac{d_1}{d_2} I_1^*, \]

\[ E_2^* = \frac{(\mu + d_2)(\Lambda - \mu N^*)}{k_2 d_2} - \frac{d_1(\mu + d_2)}{k_2 d_2} I_1^*. \] (3.40)

Substituting (3.40) into \( \beta_2(N^*)S^* I_2^* + (1 - p)r_2 I_1^* - (\mu + k_2)E_2^* = 0 \), \( N^* \) satisfies the following equation:

\[ G(N^*) = 0, \] (3.41)

where

\[ G(N^*) = \frac{\beta_1(S_0)S_0(\Lambda - \mu N^*)}{R_1} \left[ k_2 d_2 S_0 \beta_1(S_0) \beta_2(N^*) - d_2 \mu_1 - \frac{(1 - p)k_2 d_2 r_2 \beta_2(N^*)}{\beta_1(N^*)} \right] \]

\[ + d_2 \Lambda \left( 1 - \frac{\beta_1(S_0)}{\beta_1(N^*) R_1} \right) \left[ d_1 \mu_1 + (1 - p)k_2 d_2 r_2 - \frac{d_1 k_2 S_0 \beta_1(S_0) \beta_2(N^*)}{R_1 \beta_1(N^*)} \right], \] (3.42)

\[ \mu_1 = (\mu + k_2)(\mu + d_2). \]

Since \( \beta_1(N)/\beta_2(N) = \beta_1/\beta_2 \), \( \lim_{N \to 0} (1/\beta_1(N)) = +\infty \), if \( R_1 > d_1 k_2 \beta_2 S_0 \beta_1(S_0)/\beta_1[d_1 \mu_1 + (1 - p)k_2 d_2 r_2] \), then

\[ \lim_{N^* \to 0} G(N^*) = -\infty. \] (3.43)

It means that \( G(N^*) = 0 \) has only one positive root in the interval \([0, S_0]\) if \( G(N^*) \) is monotone increasing and \( G(S_0) \geq 0 \), which is equivalent to

\[ R_1 > \frac{H_1 + H_2}{H_3 + H_4}, \]

\[ R_2 < \left[ 1 + \frac{(1 - p)d_2 k_2 r_2}{d_1 \mu_1} \right] R_1, \] (3.44)
where

\[ H_1 = k_2 d_2 \beta_2 S_0 \beta_1(S_0) \beta_1^2(N^*), \]
\[ H_2 = d_1 d_2 k_2 \beta_2 S_0 \beta_1(S_0) \beta_1^2(N^*), \]
\[ H_3 = \beta_1^2(N^*) [d_2 \beta_1 \mu_1 + d_2 k_2 \beta_2 r_2 (1 - p)], \]
\[ H_4 = d_2 \beta_1'(N^*) [d_1 \beta_1 \mu_1 + d_2 k_2 \beta_1 r_2 (1 - p)]. \]

Let

\[ H = \max \left\{ 1, \frac{H_1 + H_2}{H_3 + H_4} \right\}, \]
\[ f(R_1) = \left[ 1 + \frac{(1 - p) d_2 k_2 r_2}{d_1 \mu_1} \right] R_1. \]

When

\[ R_1 > H, \quad R_2 < f(R_1), \]

it shows that \( G(S_0) \geq 0 \), and \( G(N^*) \) is monotone increasing, by the intermediate value-theorem, \( G(N^*) = 0 \) has only one positive root in the interval \([0, S_0]\), which signify that \( P_2 \) is unique. Obviously, \( S^* > 0 \). In order to make certain that \( E_1^* > 0, I_1^* > 0, E_2^* > 0, I_2^* > 0 \), we obtain that \( E_1^* > 0, I_1^* > 0, E_2^* > 0, I_2^* > 0 \) if and only if

\[ 0 < I_1^* < \frac{\Lambda - \mu N^*}{d_1}. \]

Due to \( d_2 > d_1 > 0 \), introducing (3.40) into (3.48), we acquire

\[ B_1 < R_1 < B_2, \]

where

\[ B_1 = \frac{S_0 \beta_1(S_0) [\beta_2(N^*) (\Lambda - \mu N^*) + \mu d_2]}{\Lambda d_2 \beta_1(N^*)}, \]
\[ B_2 = \frac{S_0 \beta_1(S_0) [\beta_1(N^*) (\Lambda - \mu N^*) + \mu d_1]}{\Lambda d_1 \beta_1(N^*)}, \]

and \( B_1 < B_2 \).

Now, we can get the following conclusion.
Lemma 3.7. When conditions (W1), (W2), (3.47) and (3.49) are satisfied, the system (2.2) has a unique interior equilibrium \( P_2 = (S^*, E_1^*, I_1^*, E_2^*, I_2^*) \) with \( S^*, E_1^*, I_1^*, E_2^*, \) and \( I_2^* \) all nonnegative.

Remark 3.8. For \( \beta_1(N) = \beta_1 \) and \( \beta_1(N) = \beta_1 / N \), condition (W1) is not satisfied. However, at least when \( \beta_1(N) = \beta_1 C(N) \), condition (W1) is satisfied, we also can find our conclusions are still correct from Figures 7 and 10.

3.5. Global Stability of the Interior Equilibrium

Herein, we study the global stability of the interior equilibrium \( P_2 \) of system (2.2). For simplicity, we only consider the special case when the transmission coefficients of drug-sensitive TB-strain and drug-resistant TB-strain are equal, that is, \( \beta_1(N) = \beta_2(N) = \beta(N) \), then, we get the following result.

Theorem 3.9. If conditions (W1), (W2), (3.47) and (3.49) are satisfied, interior equilibrium \( P_2 \) of system (2.2) is globally asymptotically stable when

\[
\frac{S}{S^*} = \frac{E_1}{E_1^*} = \frac{E_2}{E_2^*} \geq 1, \quad \frac{I_2}{I_2^*} \geq \frac{I_1}{I_1^*} \quad \text{or} \quad \frac{S}{S^*} = \frac{E_1}{E_1^*} = \frac{E_2}{E_2^*} \leq 1, \quad \frac{I_2}{I_2^*} \leq \frac{I_1}{I_1^*}. \quad (3.51)
\]

Proof. Following [33], we consider the Lyapunov function:

\[
U(S, E_1, I_1, E_2, I_2) = (S - S^* \ln S) + (E_1 - E_1^* \ln E_1^*) + C(I_1 - I_1^* \ln I_1^*)
+ (E_2 - E_2^* \ln E_2^*) + D(I_2 - I_2^* \ln I_2^*),
\]

where \( C \) and \( D \) are positive constants to be determined later. Differentiating this function with respect to time along the solutions of system (2.2) yields

\[
\dot{U} = \left(1 - \frac{S^*}{S}\right) S + \left(1 - \frac{E_1^*}{E_1}\right) E_1 + C\left(1 - \frac{I_1^*}{I_1}\right) I_1
+ \left(1 - \frac{E_2^*}{E_2}\right) E_2 + D\left(1 - \frac{I_2^*}{I_2}\right) I_2
= \left(1 - \frac{S^*}{S}\right) \left[\Lambda - \beta(N) S I_1 - \beta(N) S I_2 - \mu S\right]
+ \left(1 - \frac{E_1^*}{E_1}\right) \left[\beta(N) S I_1 + pr_2 I_1 - k_1(1 - r_1) E_1 - \mu E_1\right]
+ C\left(1 - \frac{I_1^*}{I_1}\right) \left[k_1(1 - r_1) E_1 - (r_1 + \mu + d_1) I_1\right]
+ \left(1 - \frac{E_2^*}{E_2}\right) \left[\beta(N) S I_2 + (1 - p)r_2 I_1 - (\mu + k_2) E_2\right]
+ D\left(1 - \frac{I_2^*}{I_2}\right) \left[k_2 E_2 - (\mu + d_2) I_2\right].
\]
Considering (3.37), we can deduce that

\[
\Lambda = \beta(N^*)S^*I_1^* + \beta(N^*)S^*I_2^* + \mu S^*, \\
\mu + k_1(1-r_1) = \beta(N^*)S^*I_1^* E_1 \frac{I_1}{E_1}, \\
\mu + d_1 + r_2 = k_1(1-r_1) E_1 \frac{I_1}{E_1}, \\
\mu + k_2 = \beta(N^*)S^*I_2^* E_2 \frac{I_2}{E_2} + (1-p)r_2 E_2 \frac{I_2}{E_2}, \\
\mu + d_2 = k_2 E_2 \frac{I_2}{E_2}.
\]

Then, (3.53) becomes

\[
\bar{U} = \left[1 - \frac{S^*}{S}\right] \left[\beta(N^*)S^*I_1^* + \beta(N^*)S^*I_2^* + \mu S^* - \beta(N)SI_1 - \beta(N)SI_2 - \mu S\right]
\]

\[
+ \left[1 - \frac{E_1^*}{E_1}\right] \left[\beta(N)SI_1 + pr_2I_1 - \beta(N^*)S^*I_1^* E_1 \frac{I_1}{E_1} - pr_2I_1^* E_1\right]
\]

\[
+ C\left[1 - \frac{I_1}{I_1}\right] \left[k_1(1-r_1)E_1 - k_1(1-r_1)E_1 \frac{I_1}{I_1}\right]
\]

\[
+ \left[1 - \frac{E_2^*}{E_2}\right] \left[\beta(N)SI_2 + (1-p)r_2I_1 - \beta(N^*)S^*I_2^* E_2 \frac{I_2}{E_2} - (1-p)r_2I_1^* E_2\right]
\]

\[
+ D\left[1 - \frac{I_2}{I_2}\right] \left[k_2E_2 - k_2E_2 \frac{I_2}{I_2}\right]
\]

\[
= -\frac{\mu(S - S^*)^2}{S} + \beta(N^*)S^*I_1^* \left[1 - \frac{\beta(N)SI_1}{\beta(N^*)S^*I_1^*}\right] \left(1 - \frac{S^*}{S}\right)
\]

\[
+ \beta(N^*)S^*I_2^* \left[1 - \frac{\beta(N)SI_2}{\beta(N^*)S^*I_2^*}\right] \left(1 - \frac{S^*}{S}\right)
\]

\[
+ \left[1 - \frac{E_1^*}{E_1}\right] \left[\beta(N^*)S^*I_1^* \left(\frac{\beta(N)SI_1}{\beta(N^*)S^*I_1^*} - E_1 \frac{I_1}{E_1}\right) + pr_2I_1^* \left(E_1 \frac{I_1}{E_1} - E_1 \frac{I_1}{E_1}\right)\right]
\]

\[
+ C\left[1 - \frac{I_1}{I_1}\right] \left[k_1(1-r_1)E_1 \left(E_1 \frac{I_1}{E_1} - I_1 \frac{I_1}{I_1}\right)\right]
\]

\[
+ \left[1 - \frac{E_2^*}{E_2}\right] \left[\beta(N^*)S^*I_2^* \left(\frac{\beta(N)SI_2}{\beta(N^*)S^*I_2^*} - E_2 \frac{I_2}{E_2}\right) + (1-p)r_2I_1^* \left(I_1 \frac{I_1}{I_1} - E_2 \frac{I_2}{E_2}\right)\right]
\]

\[
+ D\left[1 - \frac{I_2}{I_2}\right] \left[k_2E_2 \left(E_2 \frac{I_2}{E_2} - I_2 \frac{I_2}{I_2}\right)\right].
\]
Now, using (3.37), we have

\[ k_1 (1 - r_1) E_1^* = (r_2 + \mu + d_1) I_1^*, \]
\[ k_2 E_2^* = (\mu + d_2) I_2^*. \]  \hspace{1cm} (3.56)

Then, (3.55) can be rewritten as follows:

\[ \dot{U} = -\frac{\mu(S - S^*)^2}{S} + \beta(N^*) S^* I_1^* \left[ \left( 1 - \frac{\beta(N) S I_1}{\beta(N^*) S^* I_1^*} \right) \left( 1 - \frac{S^*}{S} \right) + \left( 1 - \frac{E_1^*}{E_1} \right) \left( \frac{\beta(N) S I_1}{\beta(N^*) S^* I_1^*} - \frac{E_1}{E_1^*} \right) \right] \]
\[ + pr_2 I_1^* \left[ \left( 1 - \frac{E_1}{E_1^*} \right) \left( \frac{I_1}{I_1^*} \frac{E_1}{E_1^*} \right) + \frac{C(\mu + r_2 + d_1)}{pr_2} \left( 1 - \frac{I_1^*}{I_1} \right) \left( \frac{E_1}{E_1^*} - \frac{I_1}{I_1^*} \right) \right] \]
\[ + \beta(N^*) S^* I_2^* \left[ \left( 1 - \frac{\beta(N) S I_2}{\beta(N^*) S^* I_2^*} \right) \left( 1 - \frac{S^*}{S} \right) + \left( \frac{\beta(N) S I_2}{\beta(N^*) S^* I_2^*} - \frac{E_2}{E_2^*} \right) \left( 1 - \frac{E_2^*}{E_2} \right) \right] \]
\[ + (1 - p) r_2 I_1^* \left[ \left( \frac{I_1}{I_1^*} - \frac{E_2}{E_2^*} \right) \left( 1 - \frac{E_2}{E_2^*} \right) + \frac{D(\mu + d_2)}{(1 - p) r_2 I_1^*} \left( 1 - \frac{I_2}{I_2^*} \right) \left( \frac{E_2}{E_2^*} - \frac{I_2}{I_2^*} \right) \right]. \]  \hspace{1cm} (3.57)

Now, let \((x, w_1, z_1, w_2, z_2) = (S/S^*, E_1/E_1^*, I_1/I_1^*, E_2/E_2^*, I_2/I_2^*)\) and \(g(N) = \beta(N)/\beta(N^*)\), then we get

\[ U = -\frac{\mu(S - S^*)^2}{S} + \beta(N^*) S^* I_1^* \left[ \left( 1 - g(N) xz_1 \right) \left( 1 - \frac{1}{x} \right) + \left( 1 - \frac{1}{w_1} \right) \left( g(N)xz_1 - w_1 \right) \right] \]
\[ + pr_2 I_1^* \left[ \left( 1 - \frac{1}{w_1} \right) (z_1 - w_1) + \frac{C(\mu + r_2 + d_1)}{pr_2} \left( 1 - \frac{1}{z_1} \right) (w_1 - z_1) \right] \]
\[ + \beta(N^*) S^* I_2^* \left[ \left( 1 - g(N) xz_2 \right) \left( 1 - \frac{1}{x} \right) + \left( g(N)xz_2 - w_2 \right) \left( 1 - \frac{1}{w_2} \right) \right] \]
\[ + (1 - p) r_2 I_1^* \left[ \left( z_1 - w_2 \right) \frac{1}{w_2} + \frac{D(\mu + d_2)}{(1 - p) r_2 I_1^*} \left( 1 - \frac{1}{z_2} \right) (w_2 - z_2) \right], \]  \hspace{1cm} (3.58)
\[ = -\frac{\mu(S - S^*)^2}{S} + f(x, w_1, z_1, w_2, z_2), \]
where

\[ f(x, w_1, z_1, w_2, z_2) = \beta(N^*) S^* I_1^* f_1(x, w_1, z_1) + pr_2 I_1^* f_2(w_1, z_1) + \beta(N^*) S^* I_2^* f_3(x, w_2, z_2) + (1 - p) r_2 I_1^* f_4(z_1, w_2, z_2), \]

\[ f_1(x, w_1, z_1) = (1 - g(N)xz_1) \left( 1 - \frac{1}{x} \right) + \left( 1 - \frac{1}{w_1} \right) (g(N)xz_1 - w_1), \]

\[ f_2(w_1, z_1) = \left( 1 - \frac{1}{w_1} \right) (z_1 - w_1) + \frac{C(\mu + r_2 + d_1)}{pr_2} \left( 1 - \frac{1}{z_1} \right) (w_1 - z_1), \]

\[ f_3(x, w_2, z_2) = (1 - g(N)xz_2) \left( 1 - \frac{1}{x} \right) + (g(N)xz_2 - w_2) \left( 1 - \frac{1}{w_2} \right), \]

\[ f_4(z_1, w_2, z_2) = (z_1 - w_2) \left( 1 - \frac{1}{w_2} \right) + \frac{D(\mu + d_2) I_2^*}{(1 - p) r_2 I_1^*} \left( 1 - \frac{1}{z_2} \right) (w_2 - z_2). \]

(3.59)

We can choose

\[ C = \frac{pr_2}{(\mu + r_2 + d_1)}, \quad D = \frac{(1 - p) r_2 I_1^*}{(\mu + d_2) I_2^*}. \]

(3.60)

For \( x = w_1 = w_2 \), we have

\[ f_1(x, w_1, z_1) = (1 - g(N)xz_1) \left( 1 - \frac{1}{x} \right) + \left( 1 - \frac{1}{w_1} \right) (g(N)xz_1 - w_1) \]

\[ = g(N)xz_1 \left( \frac{1}{x} - 1 + \frac{1}{w_1} \right) + 1 - \frac{1}{x} - w_1 \left( 1 - \frac{1}{w_1} \right) \]

\[ = 1 - \frac{1}{x} - w_1 + 1 \]

\[ = 2 - \frac{1}{x} - x, \]

(3.61)

which is less than or equal to zero by the arithmetic-geometric mean inequality, with the following equality if and only if \( x = 1 \)

\[ f_2(w_1, z_1) = \left( 1 - \frac{1}{w_1} \right) (z_1 - w_1) + \left( 1 - \frac{1}{z_1} \right) (w_1 - z_1) \]

\[ = (z_1 - w_1) \left( 1 - \frac{1}{w_1} - 1 + \frac{1}{z_1} \right) \]

\[ = (z_1 - w_1) \left( \frac{1}{z_1} - \frac{1}{w_1} \right) \]

\[ = 2 - \frac{w_1}{z_1} - \frac{z_1}{w_1}. \]

(3.62)
which is less than or equal to zero by the arithmetic-geometric mean inequality, with the following equality if and only if $w_1 = z_1$

$$f_3(x, w_2, z_2) = (1 - g(N)xz_2) \left(1 - \frac{1}{x}\right) + (g(N)xz_2 - w_2) \left(1 - \frac{1}{w_2}\right)$$

$$= g(N)xz_2 \left(1 - \frac{1}{w_2} + \frac{1}{x} - 1\right) + 1 - \frac{1}{x} - w_2 + 1$$

$$= 1 - \frac{1}{x} - w_2 + 1$$

$$= 2 - \frac{1}{x} - x,$$

which is less than or equal to zero by the arithmetic-geometric mean inequality, with the following equality if and only if $x = 1$.

For $w_2 \geq 1$, $z_2 \geq z_1$ or $w_2 \leq 1$, $z_2 \leq z_1$, we have

$$f_4(z_1, w_2, z_2) = (z_1 - w_2) \left(1 - \frac{1}{w_2}\right) + \left(1 - \frac{1}{z_2}\right) (w_2 - z_2)$$

$$\leq (z_2 - w_2) \left(1 - \frac{1}{w_2} - 1 + \frac{1}{z_2}\right)$$

$$= (z_2 - w_2) \left(\frac{1}{z_2} - \frac{1}{w_2}\right)$$

$$= 2 - \frac{w_2}{z_2} - \frac{z_2}{w_2},$$

which is less than or equal to zero by the arithmetic-geometric mean inequality, with equality if and only if $w_2 = z_2$.

Thus, $U(S, E_1, I_1, E_2, I_2)$ is less or equal to zero with equality only if $x = 1, w_1 = z_1, w_2 = z_2$. Since $x = w_1 = w_2$, the largest invariant set of system (2.2) on the set $\{(S, E_1, I_1, E_2, I_2) \in \mathbb{R}_+^5, U(S, E_1, I_1, E_2, I_2) = 0\}$ is the endemic equilibrium point $P_2$. By LaSalle’s invariance principle [31, 32], we can conclude that the interior equilibrium $P_2$ is globally asymptotically stable when condition (3.51) is satisfied.

**Remark 3.10.** It is possible for condition (3.51) to fail, in which case the global stability of the interior equilibrium of system (2.2) has not been established. Figures 7, 10 and 13, however, seem to support the idea that the interior equilibrium of system (2.2) is still global asymptotically stable even in this case.

### 4. Numerical Simulations

To illustrate the theoretical results contained in this paper, we give some simulations using the parameter value in Table 1. Numerical results are displayed in the following figures.

Taking no account of disease-induced death rate, we assume that $d_1 = d_2 = 0$, $\beta_1 = 0.001$, $\beta_2 = 0.0001$ (so that $R_1 < 1$, $R_2 < 1$). For $\beta_1(N) = \beta_1$, $\beta_2(N) = \beta_2$, $\beta_3(N) = \beta_1/N$,
Table 1: Description and estimation of parameters.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Description</th>
<th>Estimated value</th>
</tr>
</thead>
<tbody>
<tr>
<td>$\Lambda$</td>
<td>Recruitment rate of susceptible individuals into the community</td>
<td>2 year$^{-1}$</td>
</tr>
<tr>
<td>$\beta_1(N)$</td>
<td>Transmission coefficient of sensitive strain</td>
<td>Variable</td>
</tr>
<tr>
<td>$\beta_2(N)$</td>
<td>Transmission coefficient of resistant strain</td>
<td>Variable</td>
</tr>
<tr>
<td>$\mu$</td>
<td>Naturally death rate</td>
<td>0.01 year$^{-1}$</td>
</tr>
<tr>
<td>$k_1$</td>
<td>Rate of progression from infection to infectious for sensitive strain</td>
<td>0.005 year$^{-1}$</td>
</tr>
<tr>
<td>$k_2$</td>
<td>Rate of progression from infection to infectious for resistant strain</td>
<td>0.005 year$^{-1}$</td>
</tr>
<tr>
<td>$r_1$</td>
<td>Rate of effective chemoprophylaxis to sensitive strain</td>
<td>0</td>
</tr>
<tr>
<td>$r_2$</td>
<td>Rate of effective therapy to sensitive strain</td>
<td>0.4 year$^{-1}$</td>
</tr>
<tr>
<td>$d_1$</td>
<td>Disease-induced mortality rate of sensitive strain</td>
<td>Variable</td>
</tr>
<tr>
<td>$d_2$</td>
<td>Disease-induced mortality rate of resistant strain</td>
<td>Variable</td>
</tr>
<tr>
<td>$p$</td>
<td>Proportion of sensitive TB individuals received effective therapy that have progression to the $E_1$ class</td>
<td>0.9 year$^{-1}$</td>
</tr>
</tbody>
</table>

Figure 2: Trajectories of system (2.2) when $\beta_1(N) = \beta_1, \beta_2(N) = \beta_2, \beta_1 = 0.001, \beta_2 = 0.0001, d_1 = d_2 = 0$, so that $R_1 < 1, R_2 < 1$. It shows that the disease-free equilibrium $P_0$ is stable.

$\beta_2(N) = \beta_2/N$ and $\beta_1(N) = \beta_1 C(N), \beta_2(N) = \beta_2 C(N), C(N) = bN/(1 + bN + \sqrt{1 + 2bN}), b = 1$, Figures 2, 3, and 4 show the trajectories plots and their plane figures, respectively, which are in agreement with Theorem 3.2.

When there is disease-induced death rate, which means that $d_1 > 0, d_2 > 0$, we take $d_1 = 0.02, d_2 = 0.07$. Firstly, we consider system (2.2) with $\beta_1(N) = \beta_1, \beta_2(N) = \beta_2$ and choose $\beta_1 = 0.001, \beta_2 = 0.001$, so that $R_1 < 1, R_2 < 1$, Figure 5 presents the trajectories plot and plane figure. From this figure, we can see that the trajectories of system (2.2) converge to the disease-free
Figure 3: Trajectories of system (2.2) when $\beta_1(N) = \beta_1/N$, $\beta_2(N) = \beta_2/N$, $\beta_1 = 0.001$, $\beta_2 = 0.0001$, $d_1 = d_2 = 0$, so that $R_1 < 1$, $R_2 < 1$. It shows that the disease-free equilibrium $P_0$ is stable.

Figure 4: Trajectories of system (2.2) when $\beta_1(N) = \beta_1C(N)$, $\beta_2(N) = \beta_2C(N)$, $C(N) = N/(1 + N + \sqrt{1 + 2N})$, $\beta_1 = 0.001$, $\beta_2 = 0.0001$, $d_1 = d_2 = 0$, so that $R_1 < 1$, $R_2 < 1$. It shows that the disease-free equilibrium $P_0$ is stable.

The equilibrium. We also choose $\beta_1 = 0.001$, $\beta_2 = 1$, so that $R_1 < 1$, $R_2 > 1$, Figure 6 presents the trajectories plot and plane figure. It shows that the drug-resistant-TB-strain-only equilibrium is global asymptotically stable. Then, we choose $\beta_1 = 1$, $\beta_2 = 0.25$, so that $R_1 > H$, $R_2 < f(R_1)$, the trajectories plot and its plane figure are depicted in Figure 7, we can observe that the
Figure 5: Trajectories of system (2.2) when $\beta_1(N) = \beta_1$, $\beta_2(N) = \beta_2$, $\beta_1 = 0.001$, $d_1 = 0.02$, $d_2 = 0.07$, so that $R_1 < 1$, $R_2 < 1$. It shows that the disease-free equilibrium $P_0$ is stable.

Figure 6: Trajectories of system (2.2) when $\beta_1(N) = \beta_1$, $\beta_2(N) = \beta_2$, $\beta_1 = 0.001$, $\beta_2 = 1$, $d_1 = 0.02$, $d_2 = 0.07$, so that $R_1 < 1$, $R_2 > 1$. It shows that the boundary equilibrium $P_1$ is stable.

Trajectories converge to the unique interior equilibrium. This implies that both the sensitive and resistant strains coexist and prevail in the host population as shown in Theorem 3.9.

Next, we need to think the case when $\beta_1(N) = \beta_1/N$, $\beta_2(N) = \beta_2/N$. Figures 8, 9 and 10 show the trajectories plot and its plane figure of system (2.2) when $\beta_1 = \beta_2 = 0.001$ (so that $R_1 < 1$, $R_2 < 1$), $\beta_1 = 0.001$, $\beta_2 = 1$ (so that $R_1 < 1$, $R_2 > 1$), and $\beta_1 = 1$, $\beta_2 = 0.25$ (so
that \( R_1 > H, R_2 < f(R_1) \), respectively. As the previous cases, we can find that the trajectories of system (2.2) converge to the disease-free equilibrium when \( R_1 < 1, R_2 < 1 \) (see Figure 8), the drug-resistant-TB-strain-only equilibrium is global asymptotically stable when \( R_1 < 1, R_2 > 1 \) (see Figure 9), while the trajectories of system (2.2) converge to the unique interior equilibrium when \( R_1 > 1, R_2 < f(R_1) \) (see Figure 10).
Eventually, we assume that $\beta_1(N) = \beta_1C(N)$, $\beta_2(N) = \beta_2C(N)$, $C(N) = bN/(1 + bN + \sqrt{1 + 2bN})$ in system (2.2), of which $b = 1$. Numerical results are depicted in Figures 11, 12, and 13. Figure 11 presents the trajectories and its plane figure when $\beta_1 = \beta_2 = 0.001$ (so that $R_1 < 1$, $R_2 < 1$). From this figure, it clearly appears that the disease disappears in the host population. Figure 12 presents the trajectories and its plane figure when $\beta_1 = 0.001$, $\beta_2 = 1$ (so
that $R_1 < 1$, $R_2 > 1$), we can see that the drug-resistant-TB-strain-only equilibrium is global asymptotically stable. Figure 13 gives a description of the trajectories and its plane figure when $\beta_1 = 1, \beta_2 = 0.25$ (so that $R_1 > H, R_2 < f(R_1)$). By observation, we conclude that both the sensitive and resistant strains will coexist and prevail in the host population.
Figure 13: Trajectories of system (2.2) when $\beta_1(N) = \beta_i C(N)$, $\beta_2(N) = \beta_i (N) C(N) = N/(1 + N + \sqrt{1 + 2N})$, $\beta_1 = 1$, $\beta_2 = 0.25$, $d_1 = 0.02$, $d_2 = 0.07$, so that $R_1 > H$, $R_2 < f(R)$, It shows that the interior equilibrium $P_2$ is stable.

5. Discussion

In this paper, we studied a two-strain tuberculosis model that includes both drug-sensitive and drug-resistant strains. The novelty of our model is that we incorporate general contact rate $\beta_i(N)$, $i = 1, 2$ into a two-strain tuberculosis model. By using the Lyapunov stability theory, LaSalle’s invariant set theorem and Dulac’s criterion, the global stability of equilibria of the proposed model is proved. The basic reproduction number $R_1$, $R_2$ provide the threshold conditions which determine the competitive outcomes of the two strains. When $R_1 < 1$, $R_2 < 1$, the disease-free equilibrium $P_0$ is globally stable and the disease will die out. When $R_1 < 1$, $R_2 > 1$, a unique boundary equilibrium $P_1$ exists and is globally stable. While when $R_1 > H$, $R_2 < f(R)$, there exists a unique interior equilibrium $P_2$ which is globally asymptotically stable under certain conditions. A fairly good agreement is obtained between the analytical and numerical results.

With the appearance of numerous second-line antituberculous drugs, such as capreomycin, amikacin, and kanamycin, the treatment of drug-resistant-TB has become possible. We will leave this for future study.

Acknowledgments

This work was supported by the NNSF of China (10961018), the Key Project of Chinese Ministry of Education (209131), the Project Sponsored by the Scientific Research Foundation for the Returned Overseas Chinese Scholars, State Education Ministry, the NSF of Gansu Province of China (3ZS042-B25-013), the NSF of Bureau of Education of Gansu Province of China (0803-01) and the Development Program for Outstanding Young Teachers in Lanzhou University of Technology (Q200703) and the Doctor’s Foundation of Lanzhou University of Technology.
References


